Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non–Small Cell Lung Cancer at US Community Oncology Practices
Author:
Funder
GlaxoSmithKline
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference12 articles.
1. American Cancer Society. Cancer facts and figures, 2013. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed January 29, 2015.
2. Adjuvant chemotherapy in completely resected non–small-cell lung cancer;Pisters;J Clin Oncol,2005
3. Clinical stage I non–small cell lung cancer including FDG-PET imaging: sites and time to recurrence;Gauger;J Thorac Oncol,2007
4. Cisplatin-based adjuvant chemotherapy in patients with completely resected non–small-cell lung cancer;Arriagada;N Engl J Med,2004
5. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non–small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial;Douillard;Lancet Oncol,2006
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Prognostic impact of adjuvant therapy for cisplatin-unfit patients with non-small-cell lung cancer: A multicenter analysis;Lung Cancer;2024-02
2. Real-World Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Early-Stage Non-Small-Cell Lung Cancer;Current Oncology;2024-01-12
3. Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs;Journal of Comparative Effectiveness Research;2023-11
4. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial;Annals of Oncology;2023-10
5. Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC);PharmacoEconomics;2023-06-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3